Should a 61-year-old woman continue cervical cancer screening with Pap smear (and HPV co‑test), and what interval is recommended?

Cervical Cancer Screening at Age 61

A 61-year-old woman with adequate prior negative screening should continue cervical cancer screening until age 65, at which point she can discontinue if she meets specific exit criteria. 1

Current Screening Recommendations for Ages 30-65

For women aged 30-65 years, the American Cancer Society and joint guidelines recommend:

• Preferred approach: Co-testing with HPV and cytology every 5 years 1
• Acceptable alternative: Cytology (Pap test) alone every 3 years 1
• Emerging preferred method: Primary HPV testing alone every 5 years 2, 3, 4

At age 61, this patient should continue with one of these screening strategies until she reaches age 65 and meets discontinuation criteria. 1

Criteria to Stop Screening at Age 65

Screening can be discontinued after age 65 ONLY if ALL of the following criteria are met: 1, 5

Required Documentation of Adequate Prior Screening:

• Either: 3 consecutive negative cytology tests within the past 10 years, with the most recent within the last 5 years 1
• Or: 2 consecutive negative HPV tests (or HPV/cytology co-tests) within the past 10 years, with the most recent within the last 5 years 1, 5
• Updated 2026 guidance: HPV testing at ages 60 and 65 years is now recommended as the preferred exit strategy, with the last HPV test at age 65 or older 4

Additional Requirements:

• No history of CIN2, CIN3, adenocarcinoma in situ, or cervical cancer in the past 20-25 years 1, 5, 2
• Cervix still present (or if hysterectomy performed, it was for benign reasons only) 1
• No high-risk conditions: not HIV-positive, not immunocompromised, no in utero diethylstilbestrol exposure 1, 5

Critical Exceptions Requiring Continued Screening Beyond Age 65

Continue screening indefinitely (or for 20-25 years post-treatment) if: 1, 5

• History of CIN2, CIN3, adenocarcinoma in situ, or cervical cancer—screening must continue for at least 20-25 years after treatment, even if this extends well past age 65 1, 5
• Cannot document adequate prior negative screening through medical records (patient self-report is insufficient) 1, 5
• Immunocompromised status (HIV-positive, organ transplant recipient, chronic immunosuppression) 1, 5
• In utero diethylstilbestrol exposure 1, 5

Evidence Supporting These Recommendations

Disease Burden in Older Women:

• Approximately 20% of new cervical cancer cases are diagnosed in women ≥65 years 1, 5
• Cervical cancer deaths from diagnoses after age 65 account for approximately 25% of all cervical cancer deaths annually 1, 5
• However, 42% of women ≥65 years diagnosed with cervical cancer had never been screened or were inadequately screened 5, 6

Protective Effect of Adequate Screening:

• Among adequately screened women, the 20-year absolute risk of cervical cancer is only 8 per 10,000, compared to 49 per 10,000 in unscreened women—an 84% risk reduction 5
• Sequential negative HPV testing (with or without cytology) is associated with very low risk of cervical cancer in older women 1
• The 5-year CIN3+ risk after 2 consecutive negative co-tests in women ≥50 years is 0.036% 1

Common Pitfalls to Avoid

• Never discontinue screening without verifying adequate prior screening through medical record review—verbal patient report is insufficient 1, 5
• Do not stop screening at age 65 in women with prior CIN2+ until 20-25 years have elapsed since treatment, regardless of current age 1, 5
• Do not resume screening once discontinued for any reason, including new sexual partners, as the risk of newly acquired HPV progressing to cancer in adequately screened older women is extremely low 1, 5
• Women who underwent hysterectomy with cervix removal for benign reasons should not be screened—this provides no benefit 1, 5

Practical Algorithm for This 61-Year-Old Patient

1. Review her screening history thoroughly through medical records (not patient recall) 1, 5
2. If adequate prior screening is documented: Continue current screening strategy (co-testing every 5 years or cytology every 3 years) until age 65, then discontinue if all exit criteria remain met 1, 4
3. If screening history is inadequate or cannot be verified: Continue screening until adequate negative results are obtained, which may extend beyond age 65 1, 5
4. If history of CIN2+ or high-risk conditions: Plan for extended screening beyond age 65 per guidelines above 1, 5